Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden clot risk in lung disease patients under the microscope

NCT ID NCT07833254

Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 22, 2026 · Last updated Sep 23, 2026 · Updated 1 time

Summary

Researchers at Sohag University are observing 100 adults hospitalized with interstitial lung disease to measure how many develop deep vein thrombosis or pulmonary embolism during their stay. The team will record each patient's clinical characteristics, disease severity, and clot risk factors, then track outcomes such as length of stay, breathing support needs, ICU admission, and in-hospital mortality. The goal is to learn which ILD patients face the highest clot risk so hospitals can improve early detection and prevention.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers learn which ILD patients face the highest clot risk, hospitals could spot warning signs earlier and tailor prevention or screening to those who need it most.
What could go wrong
This is an observational study at a single center with 100 patients, so the findings may not apply to all hospitals or all ILD patients. It cannot prove that any particular prevention strategy works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

"The study will include adult patients aged 18 years or older who are admitted to the Department of Chest Diseases, Sohag University Hospital, with a confirmed diagnosis of interstitial lung disease (ILD). Eligible patients will be assessed for risk factors, clinical characteristics, and occurrence of venous thrombotic events during hospitalization.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. Patients admitted to the respiratory ICU, Chest Department Exclusion Criteria: * Age \< 18 years. Patients already receiving therapeutic anticoagulation before admission. Known inherited thrombophilia. Active malignancy. Pregnancy. Patients refusing participation. Recent major surgery or trauma within previous 4 weeks.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Deep venous thrombosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease pulmonary embolism venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Deep venous thrombosis Interstitial lung disease Pulmonary embolism Venous thromboembolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.